Guidelines for chemotherapy of biliary tract and ampullary carcinomas

[1]  日本肝癌研究会.  General rules for the clinical and pathological study of primary liver cancer , 2010 .

[2]  Masahiro Yoshida,et al.  Purpose, use, and preparation of clinical practice guidelines for the management of biliary tract and ampullary carcinomas , 2008, Journal of hepato-biliary-pancreatic surgery.

[3]  J. Furuse,et al.  S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study , 2008, Cancer Chemotherapy and Pharmacology.

[4]  H. Ueno,et al.  Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. , 2006, Japanese journal of clinical oncology.

[5]  P. Philip,et al.  Phase II study of erlotinib in patients with advanced biliary cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Choi,et al.  A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer , 2006, Journal of gastroenterology and hepatology.

[7]  S. Park,et al.  Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma , 2006, Cancer.

[8]  최진섭,et al.  Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer , 2006 .

[9]  T. Okusaka,et al.  Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer , 2006, Cancer Chemotherapy and Pharmacology.

[10]  D. Yoon,et al.  Capecitabine combined with gemcitabine (CapGem) as first‐line treatment in patients with advanced/metastatic biliary tract carcinoma , 2005, Cancer.

[11]  H. Ueno,et al.  A phase II trial of Uracil-tegafur (UFT) in patients with advanced biliary tract carcinoma. , 2005, Japanese journal of clinical oncology.

[12]  Yeul-Hong Kim,et al.  The efficacy of epirubicin, cisplatin, uracil/tegafur, and leucovorin in patients with advanced biliary tract carcinoma , 2005, Cancer.

[13]  D. Smith,et al.  Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer , 2005, British Journal of Cancer.

[14]  G. Pond,et al.  Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  E. Van Cutsem,et al.  A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. , 2005, European journal of cancer.

[16]  S. Thongprasert,et al.  Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  S. Alberts,et al.  Gemcitabine, 5‐fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma , 2005, Cancer.

[18]  S. Mani,et al.  A Phase II Trial of Fixed Dose Rate Gemcitabine in Patients With Advanced Biliary Tree Carcinoma , 2004, American journal of clinical oncology.

[19]  H. Ueno,et al.  Phase II study of S-1 in patients with advanced biliary tract cancer , 2004, British Journal of Cancer.

[20]  C. Tournigand,et al.  Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Manal M. Hassan,et al.  Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma , 2004, Cancer.

[22]  N. Yonemoto,et al.  Chemotherapy in the Treatment of Advanced Gallbladder Cancer , 2004, Oncology.

[23]  G. Pond,et al.  Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  K. Yeh,et al.  Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract , 2004, British Journal of Cancer.

[25]  E. Papalambros,et al.  Weekly Gemcitabine for the Treatment of Biliary Tract and Gallbladder Cancer , 2004, Investigational New Drugs.

[26]  D. Doval,et al.  A Phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer , 2004, British Journal of Cancer.

[27]  W. Scheithauer,et al.  Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  K. Ridwelski,et al.  Outpatient Therapy with Gemcitabine and Docetaxel for Gallbladder, Biliary, and Cholangio-Carcinomas , 2002, Investigational New Drugs.

[29]  R. Schilsky,et al.  Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma , 2004, Investigational New Drugs.

[30]  Y. Jan,et al.  A phase II trial of tegafur-uracil plus leucovorin (LV) in the treatment of advanced biliary tract carcinomas. , 2003, Japanese journal of clinical oncology.

[31]  Helen H. W. Chen,et al.  A Phase II Trial of Gemcitabine in the Treatment of Advanced Bile Duct and Periampullary Carcinomas , 2003, Chemotherapy.

[32]  H. Ueno,et al.  Phase II Study of Cisplatin, Epirubicin, and Continuous-Infusion 5-Fluorouracil for Advanced Biliary Tract Cancer , 2003, Oncology.

[33]  Z. Aziz,et al.  Prospective Evaluation of Efficacy and Toxicity of 5‐FU and Folinic Acid (Mayo Clinic Regimen) in Patients With Advanced Cancer of the Gallbladder , 2003, American Journal of Clinical Oncology.

[34]  J. Kim,et al.  Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  R. Goldberg,et al.  CPT-11 for bile-duct and gallbladder carcinoma , 2002, International journal of gastrointestinal cancer.

[36]  J. Yook,et al.  Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  T. Takada,et al.  Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? , 2002, Cancer.

[38]  H. Hass,et al.  Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial , 2002, British Journal of Cancer.

[39]  M. Ducreux,et al.  Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  Manal M. Hassan,et al.  Phase II Trial of Cisplatin, Interferon α-2b, Doxorubicin, and 5-Fluorouracil for Biliary Tract Cancer , 2001 .

[41]  V. Georgoulias,et al.  First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study. , 2001, European journal of cancer.

[42]  L. Orlandi,et al.  A phase II study of gemcitabine in gallbladder carcinoma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  Y. Jan,et al.  Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas , 2001, Anti-cancer drugs.

[44]  W. Scheithauer,et al.  Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  J. Seo,et al.  Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. , 2000, American Journal of Clinical Oncology.

[46]  T. Todoroki.  Chemotherapy for gallbladder carcinoma--a surgeon's perspective. , 2000, Hepato-gastroenterology.

[47]  M. Ducreux,et al.  A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. , 2000, European journal of cancer.

[48]  W. Scheithauer,et al.  Two Consecutive Phase II Studies of 5-Fluorouracil/Leucovorin/Mitomycin C and of Gemcitabine in Patients with Advanced Biliary Cancer , 1999, Oncology.

[49]  R. Pazdur,et al.  Phase II trial of docetaxel for cholangiocarcinoma. , 1999, American journal of clinical oncology.

[50]  T. Takada,et al.  Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial. , 1998, Hepato-gastroenterology.

[51]  R. Jenkins,et al.  A phase II trial of 5‐fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma , 1998, Cancer.

[52]  Y. Jan,et al.  Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas. , 1998, Anti-cancer drugs.

[53]  M. Ducreux,et al.  Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  G. Colucci,et al.  Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5‐fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule: Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.) , 1996, Cancer.

[55]  T. Linné,et al.  Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[56]  A. Hoque,et al.  Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  C. Charnsangavej,et al.  Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  T. Hickish,et al.  Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. , 1995, European journal of cancer.

[59]  T. Takada,et al.  Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. , 1994, Oncology.

[60]  J. Furuse,et al.  A phase II study of cisplatin in patients with biliary tract carcinoma. , 1994, Oncology.

[61]  S. Pyrhönen,et al.  Epirubicin‐Sequential Methotrexate‐5‐Fluorouracil‐Leucovorin Treatment in Advanced Cancer of the Extrahepatic Biliary System: A Phase II Study , 1994, American journal of clinical oncology.

[62]  R. Audisio,et al.  Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[63]  P. Schein,et al.  5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  C. Moertel,et al.  Eastern cooperative oncology group experience with chemotherapy for inoperable gallbladder and bile duct cancer , 1984, Cancer.

[65]  I sabel Mortara,et al.  International Union against Cancer , 1938, Nature.